医学
淋巴瘤
多发性骨髓瘤
非霍奇金淋巴瘤
骨髓
肿瘤科
移植
自体干细胞移植
内科学
造血
免疫学
干细胞
生物
遗传学
作者
J. H. C. Ho,Lin Yang,Behnam Banihashemi,Lisa Martin,Mike Halpenny,Harold L. Atkins,Mitchell Sabloff,Sheryl McDiarmid,Lothar Huebsch,Isabelle Bence‐Bruckler,Antonio Giulivi,David S. Allan
摘要
Relapsed disease remains a major obstacle following autologous haematopoietic SCT (HSCT) for non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Studies regarding the importance of detectable tumour cells in PBSC collections have been inconclusive. Patients undergoing autologous HSCT for NHL and MM between 2001 and 2006 were enrolled (n=158). PBSC grafts were assessed for clonal IgH CDR3 gene rearrangements using qualitative semi-nested PCR. In comparison to patients with PCR-positive PBSC grafts, patients negative for detectable disease had no improvement in overall survival (OS) or PFS for MM (P=0.91 and 0.91) or NHL (P=0.82 and 0.85). Further, no significant difference in OS was observed between patients with PCR-positive compared with PCR-negative PBSC grafts with aggressive NHL histology (P=0.74) or indolent disease (P=0.29). Patients with contaminating tumour cells in autologous PBSCs do not have worsened OS or PFS in MM or NHL. Tumour cells detected by sensitive molecular methods in PBSC collections may be distinct from cells contaminating marrow and appear to have limited utility in identifying patients with MM and B-cell NHL who would benefit from purging strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI